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1. Introduction 
Aneurysm is an abnormal widening or ballooning of a portion of an artery due to weakness 
in the wall of the blood vessel. Although venous aneurysms do occur, arterial aneurysms are 
much more common and severe than venous aneurysms. Aneurysmal degeneration of the 
abdominal aortic and iliac arteries is a common and frequently lethal age-related disease 
process (Baxter et al., 2008; Weintraub, 2009). Arterial aneurysm is a potentially lethal 
vascular disorder, much more common in older men with estimates of prevalence ranging 
up to 10 percent (Thompson et al., 2002). Death from a ruptured aneurysm accounts for 
about 1 percent of all the deaths in the Western world (Collin et al., 1988). Extensive 
evidence indicates that mediators of immunity and inflammation participate in the 
development of aneurysm formation (Duftner et al., 2006; Shimizu et al., 2006). However, 
the pathogenesis of the aneurysm formation and rupture remains unclear.  Recent results 
obtained from clinical and experimental studies suggest that complement, an important 
mediator for immune and inflammatory responses may contribute to the pathogenesis of 
artery aneurysms.  Here, we will extensively review the potential roles of complement in 
artery aneurysm formation and rupture.   
2. Artery aneurysms 
Artery aneurysms such as aortic, cerebral and ventricular aneurysms develop as a result of 
weakening of the vascular wall in response to the initiation of a complex extracellular matrix 
remodeling process that culminates in alterations in artery compliance and resilience 
(Powell and Greenhalgh, 1989; Schneiderman et al., 1995). Aortic aneurysm is located within 
the wall of the aorta. Typically, the widened part of the aorta is considered to be an 
aneurysm when it is more than 1.5 times its normal size. Cerebral aneurysm, also known as 
a berry aneurysm, occurs in the wall of a blood vessel in the brain. Ventricular aneurysm is a 
ballooning out of part of the wall of the heart. Most aneurysms are asymptomatic and 
undiagnosed and the rupture of aneurysms is associated with a systemic inflammatory 
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response and multiple organ dysfunctions, which remain a primary cause of death in 
patients who survive the initial surgery (Harkin et al., 2004). Aneurysm rupture has an 
overall mortality rate of 80–90 percent, and an operative mortality rate of 50 percent. Other 
than relatively high risk and costly open surgical repair, few interventional modalities are 
available to treat patients with AAA (Baxter et al., 2008; Krishna et al., 2010). This mainly 
stems from little understanding of the underlying mechanism of aortic aneurysms. 
Therefore, better understanding of the pathogenesis of artery aneurysms and developing 
more effective therapies for the treatment and prevention of artery aneurysms is imperative. 
Extensive evidence indicates that the mediators of immunity and inflammation participate in 
the development of aneurysm formation (Duftner et al., 2006; Shimizu et al., 2006). The 
aneurysm is characterized by chronic adventitial and medial inflammatory cell infiltration, 
extracellular matrix degeneration, and apoptosis of smooth muscle cells, which lead to vessel 
wall weakening, aortic dilatation and aneurysm formation (Jagadesham et al., 2008). 
Inflammatory cells accumulate in aortic aneurysm lesions with a predominance of CD4+ T ,B 
cells and macrophage, which secrete various inflammatory factors, including cytokines, 
chemokines, leukotrienes, reactive oxygen species, and immunoglobulins, contributing to the 
immune response in aneurysm lesions (Shimizu et al., 2006). Macrophages promote aneurysm 
development by secreting collagenases and elastases, which could degrade elastic lamellae 
and extracellular matrix (ECM) proteins, constituting the underlying characteristics of the 
aneurysm (Kadoglou and Liapis, 2004). Consistently, extensive evidence indicates that MMP2 
and MMP9 play critical roles in the pathogenesis of artery aneurysms, and macrophages are 
the primary source of MMP-9 production in human and mouse aneurysm tissues (Longo et al., 
2002; Thompson et al., 1995). The excessive local production of the matrix metalloproteinases 
(MMPs), which are mainly secreted from macrophages, results in the damaging of smooth 
muscle cells (SMC) and thinning of the artery wall (Allaire et al., 1998; Caird et al., 2006; 
Eliason et al., 2005; Hannawa et al., 2009; Newman et al., 1994; Palombo et al., 1999; Tanaka et 
al., 1995). Moreover, the development of aneurysms is suppressed by pharmacologic inhibition 
of MMPs, such as the use of tetracycline derivatives, or genetic alterations that eliminate the 
expression of either MMP 9 or MMP 2 (Curci et al., 2000; Mosorin et al., 2001; Pyo et al., 2000). 
Elastolytic cysteine proteases, including cathepsin,  also play a critical role in the development 
of aneurysms (Shi et al., 1999). In addition, endothelial and smooth muscle cells in aneurysm 
lesions may release an array of growth factors and cytokoines to attract inflammatory cells 
recruitment, which contributes to aneurysm development (Nicholson-Weller and Halperin, 
1993). Nevertheless, the exact underlying mechanism and cause of aneurysms are unclear. The 
risk factors for aneurysms include advanced age, male gender, smoking, hypertension, 
diabetes, obesity, high cholesterol, genetic predisposition, and atherosclerosis (Wassef et al., 
2007). Among these factors, the most common culprits are atherosclerosis and high blood 
pressure (Daugherty and Cassis, 2004; Wassef et al., 2007). Most of the abdominal aortic 
aneurysms (AAA) in humans are associated with atherosclerosis (Daugherty and Cassis, 2004; 
Wassef et al., 2007).   
Although both atherosclerosis and aneurysm are immune and inflammatory diseases, they 
have different pathogeneses. The hallmark pathologic feature of atherosclerosis is foam-cell 
formation, whereas aneurysms are typified by intense oxidative stress, inflammation, matrix 
degradation, and apoptosis of smooth-muscle cells (Miller et al., 2002; Weintraub, 2009). In 
aneurysm development, first, inflammatory leukocytes play an important role in the 
degradation of elastin and collagen in the vessel wall. Subsequent dilation of the vessel will 
trigger the vascular cells to remodel and repair to prevent vessel rupture (de Waard et al., 
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2010). Most aortic aneurysms occur in association with advanced atherosclerosis (Nordon et 
al., 2009). Atherosclerosis may induce AAA formation by causing mechanical weakening of 
the aortic wall with loss of elastic recoil, along with degenerative ischemic changes, through 
obstruction of the vasa vasorum. Many patients with advanced atherosclerosis do not 
develop artery aneurysms, while some patients for which there is having no evidence of 
atherosclerosis do develop artery aneurysms. The observed association between 
atherosclerosis and aneurysm is probably not causative; however, atherosclerosis may 
represent a nonspecific secondary response to vessel wall injury that is induced by multiple 
factors. These facts clearly indicate that aneurysm has a different pathogenesis and 
consequences for aortic walls vs. atherosclerosis. Although increasing emerging evidence 
obtained from clinical and experimental studies indicates that complement system plays a 
critical pathogenic role in the development of atherosclerosis (An et al., 2009; Halas et al., 
2005; Hansson et al., 1984; Lewis et al., 2009; Meuwissen et al., 2006; Niculescu et al., 1999b; 
Nijmeijer et al., 2003; Ross, 1999; Seifert and Kazatchkine, 1988; Vlaicu et al., 1985; Wu et al., 
2009; Yun et al., 2008), the role of complement system in the pathogenesis of aneurysm 
remains unclear. 
3. Complement activation and regulation 
3.1 Complement activation 
The complement system consists of about 30 soluble and membrane-bound proteins, and is 
activated by three distinct pathways: classical, mannose-binding lectin (MBL) and 
alternative pathways, either on pathogen surfaces or in plasma (Yu et al., 2010; Zhou et al., 
2008). Activation of these pathways depends on different molecules for their initiation (Qin 
and Gao, 2006; Zhou et al., 2008). All three activation pathways converge at the level of C3 
to form C5 convertase such as the C4bC2bC3b from classical and MBL pathways and 
(C3b)2Fbb from alternative pathway. The C5 convertase then cleaves C5 to form C5b and 
C5a. The terminal complement activation pathway is induced initially by C5b, followed by 
the sequential condensation of C6 form to C5b6, and then C7, C8, and C9. Polymerization of 
C9 bound to the C5b-8 complex forms the MAC, an end-product of the complement 
activation pathway. The MAC forms a lytic pore in the lipid bilayer membrane that allows 
the free passage of solutes and water across the membrane and destroys membrane 
integrity, followed by killing of foreign pathogens and cells (Mayer, 1984).  
The liver (mainly hepatocytes) is the main source of complement proteins, accounting for 
80%~90% of plasma complement components and their soluble regulators (Qin and Gao, 
2006). Many other non-hepatic cells including macrophage, endothelial, neutrophil and 
lymphocytes could produce complement proteins. This local synthesis of complement 
occurs in the brain, heart, lung, joints, intestine, skeletal muscle and bone marrow (Morgan 
and Gasque, 1997). It has been demonstrated that the absence of locally synthesized 
complement component C3 is capable of modulating the rejection of renal allografts in vivo 
and regulating T-cell responses in vivo and in vitro (Pratt et al., 2002). The result indicates 
that the local complement production also plays a critical role in the pathogenesis of human 
diseases such as organ rejection.   
3.2 Biological functions of complement activation byproducts 
The byproducts produced in complement activation, such as C1q, C3b, iC3b, and C4b, are 
critical opsonins for host defense against pathogen and for disposal of immune complexes 
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and dead cell debris by the phagocytosis/lysis effect of the immune cells (macrophages, 
neutrophils, natural killer [NK] cells, etc.) through their surface receptor binding to these 
byproducts. On the other hand, the small fragment byproducts such as C3a, C4a, and C5a, 
termed anaphylatoxins, also play an important role in inflammation and especially in host 
defense against parasites. These anaphylatoxins can cause mast cell and basophil 
degranulation, with the release of histamine and other substances that increase vascular 
permeability and stimulate smooth muscle constriction. C3a and C5a are potent leukocyte 
chemoattractants, and can also activate these immune effector cells by binding to cell surface 
receptors  (Haas and van Strijp, 2007). Among these anaphylatoxins, C5a has the most 
potent biological activity (Guo and Ward, 2005). 
3.3 MAC function 
The cellular response to MAC formation can be classified into two groups along a response 
continuum: lytic and sublytic. Lytic MAC formation results in colloidoosmotic swelling and 
lysis of the target (Mayer, 1984; Yu et al., 2010). Normally, MAC attacks homologous 
nucleated cells mainly through sublytic MAC because nucleated cells possess several 
protective mechanisms against the cytolytic effect of the MAC, including CD59, anti-
apoptotic genes and endocytosis/shedding of MAC (Haskard et al., 2008; Zhou et al., 2008). 
The sublytic MAC can mediate non-lethal physiological and/or pathological responses in 
autologous cells (Nicholson-Weller and Halperin, 1993).  
Biological functions of sublytic MAC include insertion into the membrane of endothelial 
cells resulting in the release of: a) bFGF and PDGF (Benzaquen et al., 1994; Halperin et al., 
1993; Shankland et al., 1999); b) interleukin-1, which stimulates the expression of pro-
inflammatory adhesion molecules such as VCAM-1 and E-selectin, and of prothrombotic 
tissue factor (Acosta et al., 1996); and c) MCP-1, which attracts monocytes and macrophages 
that contribute to the pathogenesis of the atherosclerotic plaque (Fosbrink et al., 2006; 
Torzewski et al., 1996). Consistently, we have demonstrated that sublytic MAC up-regulated 
the transcripts of these growth factors and cytokines in the plaques of the deficient CD59 
mice as well as of targeted macrophages and endothelial cells. However, the role of MAC-
induced growth factors and cytokines in the aneurysms is unclear.  
In vitro studies have shown that sublytic MAC induces following cellular signaling 
pathways (Niculescu et al., 1999a; Niculescu and Rus, 1999, 2004), which may contribute to 
the increase of the release of these growth factors and cytokines. These cellular signaling 
pathways include 1) elevated Ca2+ via Ca2+ influx through transient pore in cells, which 
partially activates PKC and other cellular signaling pathways (Carney et al., 1990; 
Papadimitriou et al., 1991); 2) G protein coupled-activation of Ras, Raf-1, MEK, ERK-1 
pathway and increased activities of ERK-1, c-jun NH2-terminal kinase JNK1 and p38 MAPK 
in many cells including endothelial cells and smooth muscle cells (Niculescu et al., 1999a; 
Niculescu and Rus, 1999; Niculescu et al., 1997); 3) activation of the PI3/Akt kinase pathway 
(Fosbrink et al., 2006; Hila et al., 2001; Niculescu et al., 1999a; Soane et al., 2001); 4) activation 
of the nuclear factors NF-κB and activator protein-1 (AP-1), which may be responsible for 
MAC-induced release of IL-6 in smooth muscle cells and IL-8 and MCP-1 in endothelial cells 
(Viedt et al., 2000) (Kilgore et al., 1996; Kilgore et al., 1997); and 5) activation of the 
JAK1/STAT3 pathway (Niculescu and Rus, 1999). These in vitro experimental results 
strongly suggest that MAC is an important mediator of cellular signals that may trigger cell 
mitogenic effects, which could explain MAC-mediated growth factor and cytokine release. 
Their activations may result from the secondary effects from the released inflammatory 
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mediators by transiently sublytic MAC and/or the direct effect from sublytic MAC, which 
have not been addressed so far.  
3.4 Complement regulation 
To prevent the potentially harmful effect of complement activation on autologous cells, 
about 10 plasma- and membrane-bound inhibitory proteins have evolved to restrict 
complement activation at different stages of activation pathways (Yu et al., 2010; Zhou et al., 
2008). The soluble plasma complement regulatory proteins include C1 inhibitor, which 
regulates C1; factor H and factor I, which regulate the cleavage of C3b and C3/C5 
convertases; C4 binding protein, which splits C4 convertase and assists factor I in the 
cleavage of C4b; and S-protein, clusterin, and serum lipids, which compete with membrane 
lipids to react with nascent C5b67 (Yu et al., 2010; Zhou et al., 2008). Moreover, three 
membrane proteins that are expressed on the surface of almost all cell types inhibit 
autologous complement activation, thereby protecting self cells from complement-mediated 
injury (Morgan, 1999). These regulators include decay-accelerating factor (DAF or CD55), 
membrane cofactor protein (MCP or CD46), and membrane inhibitor of reactive lysis 
(CD59). DAF inactivates the C3 (C4b2a and C3bBb) and C5 (C4b2a3b and C3bBb3b) 
convertases by accelerating the decay of these enzymes (Davitz et al., 1986; Medof et al., 1987; 
Nicholson-Weller et al., 1985). MCP acts as a cofactor for the cleavage of cell-bound C4b and 
C3b by the serum protease factor (Brodbeck et al., 2000). CD59 restricts MAC formation by 
preventing C9 incorporation and polymerization (Sugita et al., 1989). 
3.4.1 Anti-MAC regulator CD59 
Several lines of evidence indicate that CD59 is much more relevant than DAF, MCP and 
other complement regulators in protecting cells from MAC formation and MAC-induced 
phenomena (reviewed in (Acosta et al., 2004; Fisicaro et al., 2000)): 1) an isolated deficiency 
of DAF has been described in four families that had an unusual blood group phenotype 
termed Inab (Lin et al., 1988; Telen and Green, 1989). Although DAF was completely absent 
from all circulating cells (Reid et al., 1991), none of the propositi had symptoms suggestive 
of paroxysmal nocturnal hemoglobinuria (PNH), a complement-mediated hemolytic disease 
due to the deficiency of complement regulators such as CD59 and DAF; 2) a mDAF 
knockout mouse did not show any evidence of intravascular hemolysis (Sun et al., 1999); 
and 3) an index case report from Japan described a man who had a global deficiency of 
hCD59 due to single nucleotide deletions in the CD59 gene, which placed the gene product 
out of frame and introduced a premature stop codon. This subject expressed a severe PNH 
phenotype from the unusually young age of thirteen and also had a stroke that left him with 
permanent neurological damage (Yamashina et al., 1990). Not only does the Cd59 knockout 
out mouse exhibit a full PNH-like anemia as well as platelet activation, but it also exhibits 
progressive loss of fertility (Holt et al., 2001; Qin et al., 2009; Qin et al., 2003). Also, although 
the role of S-protein as an inhibitor of MAC formation in tissues has been suggested, the S-
protein knockout mouse did not show any detectable phenotype and instead developed 
normally and was fully fertile (Zheng et al., 1995). This indicates that, at least in mice, the S-
protein is not essential for survival nor does it play a major role in restricting complement 
activation or MAC formation. In addition to the anti-MAC role, CD59 has a complement-
independent function in regulating NK, B, and T cell activities (Longhi et al., 2007; 
Sivasankar et al., 2007). 
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3.4.2 The delicate balance between complement activation and regulation 
There is a delicate balance between complement activation and regulation on autologous 
cells, which is subject to perturbation by either increased complement activation or 
decreased regulation. The perturbation may cause a variety of immune diseases and chronic 
diseases (Yu et al., 2010). It is very likely that this delicate balance between complement 
activity and regulation differs in the different tissues because of differential expression of 
complement regulatory proteins and focal activation of complement proteins (Acosta et al., 
2004). Indeed, extensive study has shown an offset balance between complement activation 
and complement regulation, which contributes to the pathogenesis of inflammatory or 
immune diseases, such as systemic lupus erythematosus (Abe et al., 1998), rheumatoid 
arthritis (Breitner et al., 1995),Alzheimer’s disease (Gasque et al., 1995), and acute renal 
transplant rejection (Pratt et al., 2002). In the case of the development of aneurysms, there 
may be an offset balance between complement activation and regulation in the vascular 
walls, thereby leading to the development of aneurysm formation and rupture, which will 
be discussed below.   
4. Clinical evidence indicates that complement may contribute to the 
development of aneurysms 
There are a few clinical studies examining the role of complement and MAC in the 
pathogenesis of aneurysms. The results obtained from human studies only provide indirect 
evidence supporting the role of complement and highlighting the possible involvement of 
each complement activation pathway in the development and rupture of artery aneurysms 
like cerebral and aortic aneurysms.   
4.1 Complement activation and complement deposition in autoimmune disease-
associated aneurysms 
The potential role of complement in the artery aneurysms was first recognized by the study 
of autoimmune disease-associated aneurysms. Early demonstration that there is a negative 
correlation between serum immunoglobin level and complement activity in the Kawasaki 
disease patients with aneurysm provides the clinical evidence to link the potential role of 
complement to the formation of artery aneurysms (Miyata et al., 1984). Kawasaki disease 
(KD), is an autoimmune disease that manifests as a systemic necrotizing medium-sized 
vessel vasculitis and is largely seen in children under five years of age (Ozkan et al., 2007). It 
affects many organ systems, mainly those including the blood vessels, skin, mucous 
membranes and lymph nodes; however, its most serious effect is on the heart, where it can 
cause severe coronary artery aneurysms in untreated children. In 1984, Miyata et al (Miyata 
et al., 1984) conducted a study to measure the serum immunoglobin level and complement 
activity in 32 Kawasaki disease patients with or without coronary aneurysm. They (Miyata 
et al., 1984) demonstrated that the group of patients with coronary aneurysm showed 
relatively higher levels of IgG. Regardless of the presence of coronary aneurysm, the level of 
IgE in the acute phase was higher than that in the convalescent phase. In addition, the level 
of immune complexes was higher in the group of patients with coronary aneurysm. There 
was a low negative correlation between immune complexes and CH50, a clinical 
measurement for total complement activity.  
Another clinical study demonstrates that there is an extensive complement deposition in 
Behcet’s disease-related aneurysm (Yamana et al., 1988). Behçet's disease is a multisystem 
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disorder of probable autoinflammatory etiology with manifestations that can affect many 
organ systems (Gul, 2005). Its classical presentation includes recurrent oral and genital 
ulcers and skin inflammatory reactivity. Neurologic involvement is rare, as is the 
development of peripheral arterial aneurysms (1990). In 1988, Yamana et al (Yamana et al., 
1988) reported two patients with vasculo-Behçet's disease who had femoral and popliteal 
aneurysms. They found that the most interesting histological features in these patients were 
prominent fibrosis of the adventitia, including the surrounding tissue, venous occlusion, 
perivasculitis and deposits of C3, C4 and immunoglobulins (IgA, IgG and IgM) in the 
arterial wall and surrounding tissue. These findings indicate that the formation of aneurysm 
in vasculo-Behçet's disease is caused by destruction of the intimal and outer side of the 
arterial wall. Complement may participate in this destruction. Therefore, the complement 
activation/consumption from increased immune complexes in the circulation of 
autoimmune diseases may be involved in the development of aneurysms associated with 
autoimmune diseases.  
Extensive clinical and experimental evidence indicates that inflammatory aortic aneurysm is 
associated with increased incidence of autoimmune disease (Haug et al., 2003; Jagadesham 
et al., 2008). Complement plays a critical role in the pathogenesis of a variety of autoimmune 
diseases. However, the role of complement in the autoimmune-associated aneurysms 
remains unclear and requires further investigation.  
4.2 Immunoglobins and C3 deposition in aneurysms 
Gregory et al used immunoblotting techniques to compare the reactivity of IgG (detected 
with secondary goat antihuman antibody) from fourteen patients with abdominal aortic 
aneurysm (AAA) with soluble proteins extracted from normal and aneurysmal aortas 
(Gregory et al., 1996). Immunoglobulins G purified from extracts obtained from nine 
patients with no AAA were used for control experiments. They demonstrated that a unique 
band at approximately 80 kd was visualized when the filters were probed with IgG from 
eleven (79 percent) of fourteen patients with AAA compared with only one (11 percent) of 
nine control subjects. Immunoglobulins G from patients with AAA co-distributed with 
matrix fibers in normal aortic sections, particularly in the adventitia (suggestive of a 
microfibrillar component). These findings suggest that these IgGs may participate in the 
development and progression of AAA because these IgGs binding to the matrix fibers in 
artery may initiate local classical pathway activation and mediate complement attack on the 
artery wall, leading to initiation of the formation of artery aneurysms associated with 
autoimmune disease.  
This prediction was further confirmed by increased C3 deposition, along with IgG content 
in the AAA (Capella et al., 1996).  In 1996, Capella et al further demonstrated that compared 
to the amounts of IgG by subclass in normal aorta, AAA had increases of 193-fold in IgG1, 
160-fold in IgG2, 389-fold in IgG3, and 627-fold in IgG4. There was a 125-fold increase in 
immunoreactive C3 by ELISA in AAA vs normal aorta. Western immunoblotting techniques 
revealed the presence of multiple C3 degradation products in AAA. Increases in IgG1, 2, 
and 3 may be responsible for activation of complement in AAA by the classical pathway 
(Capella et al., 1996). Consistent with this finding, Stella et al (Stella et al., 1991) 
demonstrated that the interstitial matrix contained deposits of IgG, IgM and C3c together 
with an increase in type III collagen and a reduction in elastin which appeared fragmented 
and swollen. The degree of activation shown by these cell elements and the activation of 
complement suggest that the relevant antigen may have been localized in the aneurysm wall 
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at the time of observation. Taken together, the presence of complement-fixing IgG 
subclasses along with increased C3 in the aneurysm wall may be an important mechanism 
promoting matrix proteolysis in AAA.  
Moreover, in addition to C3 and IgG deposits in aneurysm, C9 were also found to deposit in 
aneurysm (Chyatte et al., 1999). Chyatte et al. conducted immunohistochemistry studies 
with aneurysm tissue collected at the time of microsurgical repair from 23 unruptured and 
two ruptured aneurysms (25 patients) and compared with 11 control basilar arteries 
harvested at autopsy. Immunohistochemistry revealed the localization of complement (C3c, 
C9) and immunoglobulins (IgG, IgM) with inflammatory cells such as macrophages and 
monocytes (CD68), T lymphocytes (CD3), and B lymphocytes (CD20). Complement (C3c), 
immunoglobulin (IgG), macrophages (CD68), and T lymphocytes (CD3) were all frequently 
present in the wall of aneurysm tissue but were rarely identified in control basilar arteries. A 
few B lymphocytes (CD20) were found in aneurysm tissue, but none were found in the 
basilar arteries. Extensive inflammatory and immunological reactions are common in 
unruptured intracranial aneurysms and may be related to aneurysm formation and rupture. 
These results strongly suggest that the IgM and/or C3 and MAC deposits located in the 
endothelium of intracranial arteries may play a role in aneurysm-associated neurological 
complications. 
4.3 Complement activation in ruptured aneurysm associated with hemorrhage 
The roles of complement and complement activation in ruptured aneurysms were further 
investigated by several independent groups. In 1987, Ostergaard et al, (Ostergaard et al., 1987) 
monitored circulating immune complexes and complement activation (plasma C3d levels) 
during a two week period in patients with ruptured cerebral aneurysms and also in patients 
with cerebral hematoma unrelated to saccular aneurysms. They found that thirteen of eighteen 
aneurysm patients were found to have immune complexes on admission as compared to three 
of 21 healthy blood donors. The presence of immune complexes in aneurysm patients was 
associated with a poor prognosis. Patients with vasospasm showed a twofold increase in 
plasma C3d levels at the time when the spasm occurred, whereas no significant changes in the 
C3d concentration could be demonstrated in aneurysm patients without spasm or in patients 
with hematoma unrelated to aneurysm rupture. These findings suggest that complement-
activation mediated by immune complex are involved in the pathogenesis of cerebral 
vasospasm following rupture of saccular aneurysms (Ostergaard, 1989).  
Kawano et al. investigated serum complements (CH50, C3, C4) after aneurysmal 
subarachnoid hemorrhage in 21 patients over a two to three week period (Kawano and 
Yonekawa, 1990). Preoperative grading was well correlated with the C4 level but not the C3 
level. C4 levels in patients without symptomatic vasospasm did not change markedly after 
subarachnoid hemorrhage over investigation. There were no remarkable changes of serum 
complements in the control patients. C3 and C4 levels of the patients without symptomatic 
vasospasm did not change markedly after subarachnoid hemorrhage, while they decreased 
severely in patients with severe vasospasm and majorneurological deficit. The patients with 
mild symptomatic vasospasm without major neurological deficit showed transient decrease 
of C3 and C4 levels within a period of five to ten days after subarachnoid hemorrhage. 
These results show that sequential determinations of serum complement (C3 and C4) levels 
after subarachnoid hemorrhage is a useful method for the choice of therapy and for the 
prognosis of aneurysmal patients after subarachnoid hemorrhage. The reduction of plasma 
C3 and C4 in patients with aneurysmal vasospasm indicates that complement have been 
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activated before rupture of the aneurysm. These results further support the role of 
complement activation in the pathogenesis of aneurysmal hemorrhage (Kawano and 
Yonekawa, 1990). 
4.4 Complement including MAC deposits in ruptured aneurysm associated with 
hemorrhage  
Complement including MAC deposition in ruptured intracranial aneurysm has been 
extensively investigated in clinical samples.  An intracranial aneurysm is an important 
acquired cerebrovascular disease that can cause a catastrophic subarachnoid hemorrhage. 
Despite modern therapy, most patients die or are left disabled as a direct result of a severe 
initial hemorrhage. The development of more effective treatment strategies depends on 
understanding the fundamental biology of cerebral aneurysms. The presence of IgM and/or 
C3 in the endothelium of intracranial aneurysms was demonstrated in five out of six 
patients with subarachnoid hemorrhage (SAH) (Ryba et al., 1992). In none of them were the 
immune deposits found in the gyrus rectus. Cortical tissue of four epileptic patients which 
served as a control gave negative results. 
Complement activation associated with the rupture and subarachnoid hemorrhage of 
sacculare cerebral artery aneurysm (SCAA) was also examined by electromicroscopy and 
immunoelectron microscopy. Tulamo et al recently demonstrated that MAC localized 
consistently in a decellularized layer in the outer SCAA wall, and was found in all SCAA 
samples (Tulamo et al., 2006). The percentage of MAC-positive area relative to the total 
SCAA wall surface area was greater in ruptured than in unruptured SCAAs. It was also 
associated significantly with SCAA wall degeneration, de-endothelialization, and CD163+ 
macrophage and T-lymphocyte infiltrations. Apoptotic terminal deoxynucleotidyl 
transferase-mediated deoxyuridine triphosphate nick end-labeling-positive nuclei and MAC 
were located at the same wall areas in four out of 14 double-stained samples, but no double-
positive cells were found. Electromicroscopy and immunoelectron microscopy of an 
unruptured SCAA showed cell death in the MAC-positive layers in the outer SCAA wall. 
These results suggest that complement activation and MAC formation are involved in 
SCAA wall degeneration and rupture (Tulamo et al., 2006).   
4.5 Local classical complement activation may be involved in aneurysm formation 
and rupture  
Tulamo et al further investigated initiators and the pathway of complement activation in 
unruptured and ruptured intracranial aneurysms (Tulamo et al., 2010a). Unruptured and 
ruptured intracranial aneurysm wall samples were studied in parallel sections by 
immunohistochemical and immunofluorescence stainings. Classical pathway components 
such as C1q, C3b/iC3b, C3d, C4b/iC4b and MAC were seen in all intracranial aneurysms, 
and they were located mostly in the extracellular matrix. The early pathway complement 
components co-localized with each other, but were present in larger areas than C5b-9. The 
areas positive for complement component accumulation were significantly broader in 
ruptured than in unruptured intracranial aneurysms. The potential complement activators 
IgG, IgM, CRP and OxLDL were found mostly in the extracellular matrix and in partial 
overlap with MAC. These results indicate that immunoglobulins, CRP, and OxLDL may 
locally activate classical complement pathway, thereby leading to complement and MAC 
deposits in the intracranial aneurysms wall, which participates in the formation and rupture 
of aneurysms  (Tulamo et al., 2010a).  
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Furthermore, Tulamo et al also reported that the complement regulatory capacity of the 
complement system thus appears disturbed in the outer part of the intracranial aneurysms 
(IA) wall (Tulamo et al., 2010b). The outer part of the IA walls, where MAC is mainly 
localized in, lacked CD59 and cellular parts in comparison to normal controls. In contrast, 
complement inhibitors factor H, C4b binding protein, and CD59 as well as 
glycosaminoglycans were sufficient in the luminal part of the IA wall where MAC was 
lacking from (Tulamo et al., 2010b). Thus, these human studies indicate that dysregulation 
of the complement system, such as loss of CD59 in the outer intracranial aneurysm walls 
leads to an increased susceptibility to complement activation and MAC formation which 
may associate with inflammation and aneurysm formation.  The insufficiency of 
complement regulation may be due to matrix remodeling and cell loss by mechanical 
hemodynamics and/or inflammatory stress (Tulamo et al., 2010b). Therefore, there is an 
imbalance between complement activation and regulation in the outer part of the 
intracranial aneurysms wall, which results from more complement activation and less 
complement regulation. This imbalance may allow full pro-inflammatory complement 
activation to occur before aneurysm rupture.  
In contrast, whether alternative and lectin pathways are involved in the aneurysm formation 
and rupture remains unclear. Recently, Bradley et al (Bradley et al., 2010) demonstrated that 
there was no evidence for significant association between presence or size of aneurysm with 
49 single nucleotide polymorphisms, including common putatively functional 
polymorphisms, in the genes of the alternative complement cascade (CFH, CFB, CFD, CFI, 
properdin, CR1, CR1L, CR2, CD46, vitronectin, C3, C5, C6, C7, C8A, C8B, C8G and C9). This 
study suggests that variation in the genes of the alternative pathway is not an important 
cause of AAA development. However, the relative role of each of the  complement 
activation pathways in the pathogenesis of artery aneurysms still warrants further 
investigation. This is because 1) complement system is a critical mediator of the 
inflammatory process; and 2) the complement-mediated inflammatory process results from 
imbalance between complement activation and regulation, which highly depends on the 
sites and tissues of complement activation.  
4.6 Complement participates in the ischemia-reperfusion injury of the patients 
undergoing the surgery for aneurysm repair   
Although open surgical repair is highly costly and has high mortality rate, it still is a 
common approach for the treatment of aortic aneurysm because few interventional 
modalities are available to treat patients with aortic aneurysm (Baxter et al., 2008; Krishna et 
al., 2010). Since complement activation contributes to ischemia-reperfusion injury, it is 
conceivable that patients undergoing thoracoabdominal aortic aneurysm repair suffer 
extensive ischemia-reperfusion and considerable systemic inflammation. Consistent with 
this prediction, Odegard et al (Odegard et al., 2007) reported that preoperatively, the 
thoracic aortic aneurysms patients had significantly elevated concentrations of 
myeloperoxidase, neopterin and complement activation products compared to controls. 
Myeloperoxidase and lactoferrin increased after the first contrast dose and peaked at 8 h 
postoperatively. Platelet counts decreased, while soluble MAC increased from 8 h 
postoperatively. This result indicates that stent graft treatment induces further activation, 
and markers of endothelial, platelet, and complement activation were increased for several 
days after the procedure. 
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4.6.1 Lectin pathway activation participates in the ischemia-reperfusion injury of 
patients undergoing surgery for aneurysm repair  
Norwood et al reported that there is the consumption of MBL during AAA repair (Norwood 
et al., 2006). They demonstrated that 23 patients undergoing AAA repair experienced a 
mean decrease in plasma MBL levels of 41 percent representing significant lectin pathway 
activation (p = 0.003). In contrast, no lectin pathway activation could be demonstrated in 
eight control patients. The consumption of MBL occurs during AAA repair and is indicative 
of an important role for the lectin pathway in the ischemia-reperfusion injury associated 
with aortic aneurysm repair.  
The degree and mechanism of complement activation and its role in inflammation were 
further investigated in the patients undergoing thoracoabdominal aortic aneurysm (TAAA) 
repair by Fiane et al (Fiane et al., 2003). Substantial complement activation was seen in 
TAAA patients but not in controls. C1rs-C1-inhibitor complexes increased moderately, 
whereas C4bc, C3bBbP, C3bc, and the soluble C5b9 (MAC) increased markedly after 
reperfusion, reaching a maximum at eight hours after reperfusion. Interleukin (IL)-1, tumor 
necrosis factor α (TNF-α), and IL-8 increased significantly in TAAA patients but not in 
controls, peaking at 24 hours postoperatively and correlating closely with the degree of 
complement activation. IL-6 and IL-10 increased to a maximum 8 hours after reperfusion in 
the TAAA patients, were not correlated with complement activation, and increased 
moderately in the control subjects. Furthermore, no increase was observed in complement 
activation products, IL-1, TNF-α, or IL-8 in a MBL–deficient TAAA patient, whereas IL-6 
and IL-10 increased as in the controls. Two other MBL-deficient TAAA patients receiving 
plasma attained significant MBL levels and showed complement and cytokine patterns 
identical to the MBL-sufficient TAAA patients. These results strongly suggest that 
complement activation during TAAA repair is MBL mediated, amplified through the 
alternative pathway, and responsible in part for the inflammatory response (Fiane et al., 
2003). 
Altogether, these clinical results suggest that complement contributes to the formation and 
rupture of artery aneurysm and plays a critical role in ischemia-reperfusion injuries 
associated with aortic aneurysm repair.  However, the underlying molecular and cellular 
mechanisms, through which complement participates in the pathogenesis of artery 
aneurysm still remains unclear. Therefore, there is a strong need to experimentally dissect 
the mechanisms in animal models.  
5. Animal studies 
5.1 Current animal model of aneurysms 
Experimental models of artery aneurysms played an important role in understanding  
the underlying mechanism of artery aneurysms. A number of chemically induced AAA 
mouse models have been used extensively for the study of aneurysm pathogenesis 
(Daugherty and Cassis, 2004). These chemical approaches include intraluminal infusion of 
elastase, periaortic incubations of calcium chloride, and subcutaneous infusion of 
angiotensin II (Ang II) in Apoe-/-background (Daugherty and Cassis, 2004). These mouse 
models can recapitulate some pathological features of human aneurysms, including medial 
degeneration, inflammation, thrombus formation, and rupture (Daugherty and Cassis, 
2004). 
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5.2 Complement-dependent neutrophil recruitment is critical for the development of 
elastase-induced AAA in mice  
Transient perfusion of the abdominal aorta with a porcine elastase solution reproducibly 
leads to the formation of AAA in all C57BL/6 WT mice.  In this elastase-induced model of 
AAA, Pagano, M.B et al reported that mice that were treated with cobra venom factor(CVF, 
a potent complement inhibitor with the ability to deplete serum C3),  before or 24 hours 
after elastase perfusion, were resistant to elastase-induced AAA, characterized by smaller 
aortic dilatation, well-preserved elastic fibers, significantly less smooth muscle cell 
depletion, reduced numbers of macrophages, and activity of mast cells (Pagano et al., 2009). 
These results indicate that complement activation was involved in elastase-induced AAA 
development. Examination of mice deficient in factor B further indicated that the alternative 
pathway of complement played a major role in this process. Activation of the alternative 
pathway led to generation of the anaphylatoxins C3a and C5a, which recruited neutrophils 
to the aortic wall. Moreover, antagonism of both C3a and C5a activity was required to block 
AAA, which suggests that each can independently promote the aneurysmal phenotype. In 
addition, Pagano, M.B et al demonstrated that complement alternative-pathway 
involvement was not restricted to this experimental model, but was instead also evident in 
human AAA (Pagano et al., 2009). These results indicate that complement dependent 
neutrophile recruitment is critical for the development of AAA. 
5.3 Complement may play a role in canine subarachnoid hemorrhage models  
Gao et al (Gao et al., 2009) investigated the correlation between sympathetic nerve 
activation and inflammatory response in the acute stage of subarachnoid hemorrhage 
(SAH) in a canine perforating model. SAH was induced by perforation of the basilar 
artery with the use of a microcatheter via the femoral artery in twenty mongrel dogs. They 
demonstrated that the peak values of C3a and soluble MAC in plasma correlated 
positively with the peak value of noradrenaline. The peak values of IL-6 and IL-8 also 
correlated positively with the peak values of noradrenaline. These results suggest that a 
pronounced activation of the sympathetic nervous system and the inflammatory response 
occur in the acute stage of SAH and highlight that sympathetic activation and immune 
responses such as complement activation are quantitatively linked in the early stage after 
SAH (Gao et al., 2009). These results further support the potential role of complement 
activation in the aneurysm rupture.  
5.4 C5a receptor antagonist attenuates multiple organ injury in a model of ruptured 
AAA in rats   
The C5a-C5a receptor pathway may also play a critical role in multiple organ injuries after 
aneurysm rupture. Harkin et al (Harkin et al., 2004) examined the role of a novel 
complement factor 5a (C5aR) receptor antagonist, the cyclic peptide AcF-(OpdChaWR), in 
attenuation of pathologic complement activation and tissue injury in a model of AAA 
rupture. They demonstrated that C5aR antagonist AcF treatment significantly reduced lung 
and intestinal permeability index and myeloperoxidase activity and down-regulated lung 
TNF-alpha levels. These results indicate that a potent antagonist of C5a receptor protects the 
rat intestine and lung from neutrophil-associated injury in a model of AAA rupture. These 
data suggest that complement-mediated inflammation can be modulated at the C5a receptor 
level, independent of pro-inflammatory TNF-alpha production, and can prevent acute local 
and remote organ injury (Harkin et al., 2004). 
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5.5 Protective role of CD59 and potential pathogenic role of MAC in the AAA model  
Extensive evidence from human and animal studies indicates a protective role of CD59 and an 
atherogenic role of MAC in the pathogenesis of atherosclerosis (Wu et al., 2009). In a well-
accepted rabbit model of atherosclerosis induced by a 3 percent cholesterol diet, the deficiency 
of C6, a necessary complement for formation of MAC, protected against the development of 
atherosclerosis (Schmiedt et al., 1998; Seifert et al., 1989; Seifert and Kazatchkine, 1988). 
Recently, four independent groups defined the anti-atherogenic role of CD59 using mCd59 
deficient mice (An et al., 2009; Lewis et al., 2009; Wu et al., 2009; Yun et al., 2008). Furthermore, 
we (Wu et al., 2009)* and Lewis et al (Lewis et al., 2009) have recently documented the in vivo 
atherogenic roles of MAC using anti-mouse C5 antibody (Ab) to block the formation of MAC 
in mCd59 deficient mice and using mC6 deficient mice to block the formation of MAC 
respectively. Moreover, MAC mediated endothelial damage and promoted foam cell 
formation (Wu et al., 2009). These combined results highlight the atherogenic role of MAC 
(Wu et al., 2009). Although atherosclerosis and AAA have different pathogeneses, they are all 
immune and inflammatory diseases. Atherosclerosis is considered to be a main cause of AAA, 
thus the atherogenic role of MAC shed light on its possible role in aortic aneurysm. 
Moreover, human studies have suggested that MAC may play a role in the formation and 
rupture of aorta aneurysms as we discussed above. Taken together, this evidence prompted 
us to explore the role of MAC in the pathogenesis of AAA with our recent generation of 
both anti-MAC inhibitor CD59 deficient and overexpressing mice (Qin et al., 2009; Wu et al., 
2010). In an angiotensin (Ang) II-induced AAA model, deficiency of both mouse Cd59a and 
Cd59b (mCd59ab-/-) in ApoE-null mice accelerated the disease development, while 
transgenic over-expression of human CD59 in the endothelial and circulating 
cells(macrophages and platelets) (hCD59ICAM-2+/-) attenuated AAA progression (Wu et al., 
2010), these results suggest a protective role of CD59 in AAA development. Staining of the 
aneurysm sections with anti–C9-specific antibodies revealed that mCd59ab-/-/ApoE-/- mice 
had significantly more extensive deposits of C9 than ApoE-/- mice and that ApoE-/- mice 
have significantly more deposits of C9 than hCD59ICAM-2+/-/ApoE-/-mice. The fact that 
deposition of MAC in the AAA Lesions correlated with the severity of AAA strongly 
supports a pathogenic role of MAC in the development of AAA (Wu et al., 2010). 
Macrophage plays a critical role in the development of aorta aneurysms. Macrophages are the 
primary source of MMP-9 production in human and mouse AAA (Longo et al., 2002; 
Thompson et al., 1995). Consistent with the pathogenic role of MMPs, AAA aortic extracts 
from mCd59ab-/-/ApoE-/- mice exhibited significantly higher MMP2 and MMP9 activities, 
whereas extracts from hCD59ICAM-2+/-/ApoE-/- mice showed lower activities than ApoE-/- 
mice. Meanwhile, in the AAA lesions of mCd59ab-/-/ApoE-/- mice, the macrophage content is 
significantly increased, which is consistent with higher levels of MMP2 and MMP9 and the 
severity of AAA in this model (Wu et al., 2010). Furthermore, in vitro study demonstrated that 
sublytic MAC treatment in mouse endothelial, macrophage, and smooth muscle cells (SMC) 
increased MMP2 and MMP9 activities (Wu et al., 2010). Twelve hours after MAC treatment on 
these cells, activities of MMP2 or MMP9 from the cell extracts significantly increased. Further 
studies demonstrate that MAC upregulates MMP2 and MMP9 activities through AP-1 and 
NF-κB signaling pathways. Western blot assay revealed significantly increased 
phosphorylation of c-Jun, c-Fos, IKK-a/b and p65 in lesions of mCd59ab-/-/ApoE-/- mice, 
whereas decreased phosphorylation in hCD59ICAM-2-/-/ApoE-/-. Firefly luciferase reporter gene 
assay and RNA interference assay confirmed that MAC-activated c-Jun and NF-κB signaling 
pathways participate in the upregulation of MMP2 and MMP9, which may in turn contribute 
to the pathogenesis of AAA in Ang-II-induced AAA model.  
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It was previously demonstrated that MAC induced more severe endothelial dysfunction in 
mCd59ab-/-/ApoE-/- mice than in ApoE-/-, which contributes to atherogenesis (Wu et al., 
2009). MAC also mediates endothelial cell apoptosis in vitro. MAC insertion into endothelial 
and other cell membranes releases an array of growth factors and cytokoines, which may 
participate in the development of aneurysms. 
 
 
Fig. 1. Potential roles of complement in the pathogenesis of artery aneurysms 
MBL: Mannose Binding lection pathway, oxLDL: Oxidized low density lipoprotein, CRP: 
ECM: extracellular matrix and MAC: Membrane attack complex. 
Furthermore, the supernatant obtained from MAC-treated endothelial cells triggers the 
migration of both MAC-treated and non–MAC-treated macrophage in vitro. The increase in 
macrophage migration may result from the release of growth factors and cytokines induced 
by sublytic MAC assembly in endothelial cells. These findings suggest that MAC may 
promote AAA development through different target cells or signal pathways. In Ang-II 
induced AAA model, increased MMP expression in the aorta in AAA could be caused by 
increased macrophage infiltration, upregulation by increased MAC tissue levels, or some 
combination of these two mechanisms. 
Our study strongly supports the hypothesis that MAC may accelerate the initiation and 
development of AAA through mediation of endothelial dysfunction, attraction and 
activation of macrophages, which lead to the secretion of MMP2 and MMP9 that destroy the 
wall of blood vessels and thereby form aneurysm (Fig. 1). Taken together, these results shed 
light on the important pathogenic role of MAC in aneurysms, point towards the molecular 
mechanism of MAC-activated signaling pathways in aneurysm, and suggest inhibition of 
MAC may provide a novel approach for the treatment/prevention of aneurysms.  
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6. Conclusion 
In this review we summarized an increase in clinical and experimental evidence on the 
potential role of complement system in aortic aneurysms. The role of complement and MAC 
in artery aneurysms has only been suggested in human studies and has not been extensively 
studied in experimental models. Complement activation in the circulation has been 
identified in the course of the formation and rupture of artery aneurysms. Complement and 
MAC extensively deposit in aneurysm walls and more in rupture aneurysms than 
unruptured aneursyms. Complement also plays a critical role in the pathogenesis of 
reperfusion-ischemic injury after aneurysm repair.  Experimental evidence indicates that 
C3a and C5a play a critical role in the development of elastase-induced AAA, CD59 plays a 
critical protective role, and MAC plays a critical pathogenic role in the development of 
AAA. Together, these finding lead us to postulate the following hypothesis that 1) after 
complement is activated by one or three complement activation pathways in the circulation, 
the MAC, a terminal complement activation product, mediates endothelial dysfunction in 
the artery wall. This process will lead to the migration of inflammatory cells such as 
macrophage, the promotion of the interaction with the damaged endothelial cells, and 
deposition of activated complement bioproducts such as C3a and C5a and MAC, and 
complement activators such as immunoglobins, CRP and OxLDL in the artery wall; 2) the 
deposition of immuneglobin and CRP, OxLDL locally activates the classical complement 
activation pathways; 3) complement activation byproducts such as C3a and C5a and MAC 
amplify the inflammatory process in the artery wall through the release of inflammatory 
mediators and the attraction of more inflammatory cells to the artery wall; 4) these 
inflammatory process mediate the release of MMP2 and MMP9, which will degrade the 
elastic lamellae and extracellular matrix and damage the smooth muscle cells, finally 
leading to artery wall weakening and the formation of aneurysm or even aneurysm rupture 
(Fig. 1).  
Although the emerging evidence supports the role of complement in the pathogenesis of 
artery, there are still a number of questions that remain to be further studied.  For example, 
the molecular and cellular mechanisms of C3a, C5a, and MAC, and the relative role of 
complement activation pathways in the pathogenesis of artery aneurysms still require 
further investigation with these different animal models. Whether the early complement 
components play a role in the pathogenesis of aneurysms has not been studied so far.  
Whether the restriction of complement activation and MAC formation serves as a novel 
approach for the treatment/prevention of aneurysm also warrants future studies.  
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